Cervical adenocarcinoma identification by testing for chromosomal abnormalities

Janet L Dittus; Bunyan S Dudley; Madhvi Upender; Gregory A Endress

doi:10.5858/arpa.2012-0499-CR

Cervical adenocarcinoma identification by testing for chromosomal abnormalities

Arch Pathol Lab Med. 2013 Dec;137(12):1829-31. doi: 10.5858/arpa.2012-0499-CR.

Authors

Janet L Dittus¹, Bunyan S Dudley, Madhvi Upender, Gregory A Endress

Affiliation

¹ From the Department of Gynecologic Oncology, Tennessee Oncology, Nashville, Tennessee (Dr Dudley); and NeoDiagnostix, Rockville, Maryland (Dr Upender and Mr Endress). Dr Dittus is in private practice, Nashville, Tennessee. Dr. Upender is now the CEO of Naveenum, Potomac, Maryland. Mr Endress is a full-time employee and stockholder of NeoDiagnostix, which provided clinical lab testing during the care of the patient. The other authors have no relevant financial interest in the products or companies described in this article.

PMID: 24283864
DOI: 10.5858/arpa.2012-0499-CR

Abstract

We report on a case of cervical adenocarcinoma in situ in a 42-year-old woman with a history of human papillomavirus infection. Repeat cytology, human papillomavirus testing, and colposcopy failed to identify the lesion. Testing of the cervical cell DNA identified chromosomal abnormalities, prompting a cervical cone biopsy, which identified adenocarcinoma in situ.

Publication types

Case Reports

MeSH terms

Adenocarcinoma / diagnosis*
Adenocarcinoma / genetics*
Adenocarcinoma / pathology
Adult
Biopsy
Cervix Uteri / pathology
Chromosome Aberrations*
DNA, Neoplasm / genetics
Early Detection of Cancer
Female
Genetic Testing
Humans
Uterine Cervical Neoplasms / diagnosis*
Uterine Cervical Neoplasms / genetics*
Uterine Cervical Neoplasms / pathology

Substances

DNA, Neoplasm